The advantage of specific intravenous immunoglobulin (sivig) on regular IVIG: Experience of the last decade

Journal of Clinical Immunology

Volumn 33, Issue SUPPL.1, 2013, Pages

  Svetlicky, Nina ^a   Ortega Hernandez, Oscar Danilo ^a   Mouthon, Luc ^b   Guillevin, Loic ^b   Thiesen, Hans Jurgen ^c   Altman, Arie ^a   Kravitz, Martine Szyper ^a   Blank, Miri ^a   Shoenfeld, Yehuda ^a,d  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

anti myeloperoxidase; autoimmune diseases; inflammation; Specific IVIG; vasculitis

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; FC RECEPTOR; IMMUNOGLOBULIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SIALIC ACID;

ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHURG STRAUSS SYNDROME; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TARGETING; EXPERIMENTAL MOUSE; GLOMERULONEPHRITIS; HEART INFARCTION; HUMAN; IDIOPATHIC NECROTIZING GLOMERULONEPHRITIS; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; MICROSCOPIC POLYANGIITIS; MYASTHENIA GRAVIS; NONHUMAN; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SMALL VESSEL VASCULITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIGENS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS;

EID: 84872621110     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9842-5     Document Type: Review

References (59)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747-55.
2. Durandy A, Wahn V, Petteway S, Gelfand EW. Immunoglobulin replacement therapy in primary antibody deficiency diseases-maximizing success. Int Arch Allergy Immunol. 2005;136(3):217-29. (Pubitemid 40529193)
3. Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med. 2005;5(4):135-40. (Pubitemid 41813757)
4. Krause I, Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions. Methods Mol Med. 2005;109:403-8.
5. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: State of the art. Clin Rev Allergy Immunol. 2005;29(3):167-72. (Pubitemid 43041667)
6. Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev. 2009;9(2):124-7.
7. Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9(6):441-8.
8. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins-a review of the literature. Clin Rev Allergy Immunol. 2010;38(2-3):201-69.
9. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320(5874):373-6. (Pubitemid 351555659)
10. Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003;24 Suppl 4:S217-21. (Pubitemid 37304326)
11. Huang HS, Sun DS, Lien TS, Chang HH. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood. 2010;116(23):5002-9.
12. Le Pottier L, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y, et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol. 2007;27(3):257-65. (Pubitemid 46790821)
13. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-33. (Pubitemid 351600384)
14. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses. Immunol Rev. 1989;110:135-49. (Pubitemid 19216013)
15. Séïté JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood. 2010;116(10):1698-704.
16. Séïté JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev. 2008;7(6):435-9.
17. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3. (Pubitemid 28483679)
18. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): Trophoblast invasiveness and APS animal model. Int Immunol. 2007;19(7):857-65. (Pubitemid 47241894)
19. Blank M, Nur I, Toub O, Maor A, Shoenfeld Y. Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol. 2005;29(3):213-7. (Pubitemid 43041672)
20. Damianovich M, Blank M, Raiter A, Hardy B, Shoenfeld Y. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). Int Immunol. 2009;21(9):1057-63.
21. Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2008;194(1-2):89-96.
22. Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, et al. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2010;162(3):543-9.
23. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161(7):3781-90.
24. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol. 2002;14(11):1303-11. (Pubitemid 35331427)
25. Vassilev TL, Kazatchkine MD, Duong Van Huyen JP, Mekrache M, Bonnin E, Mani JC, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood. 1999;93(11):3624-31. (Pubitemid 29249807)
26. Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009;18(10):884-8.
27. Asherson RA. The antiphospholipid syndrome II: autoimmune thrombosis. 1st ed. Amsterdam: Elsevier; 2002.
28. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet. 2006;23(1):1-13.
29. Meroni PL, Tedesco F, Locati M, Vecchi A, Di Simone N, Acaia B, et al. Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view. Lupus. 2010;19(4):453-6.
30. Shoenfeld Y, Blank M, Sherer Y. Induction and treatment of the antiphospholipid syndrome-lessons from animal models. Eur J Clin Invest. 2001;31(8):736-40. (Pubitemid 32756623)
31. Konova E, Atanasova M, Stoykov S, Velkova A, Shoenfeld Y. Idiotypic and anti-idiotypic elastin autoantibodies: Implications for IVIg and pregnancy loss. J Autoimmun. 2007;28(1):46-54. (Pubitemid 46274176)
32. Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun. 2010;36(2):135-41.
33. Gajdos P, Chevret S. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Ann N Y Acad Sci. 2008;1132:271-5. (Pubitemid 351841344)
34. Heupel WM, Zillikens D, Drenckhahn D, Waschke J. Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction. J Immunol. 2008;181(3):1825-34.
35. Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev. 2012;11(3):226-30. Epub 2011 May 27.
36. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595-603.
37. Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Br J Dermatol. 2009;160(5):1098-102.
38. Guillevin L, Pagnoux C, Mouthon L. Churg-strauss syndrome. Semin Respir Crit Care Med. 2004;25(5):535-45. (Pubitemid 39518248)
39. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512-23. (Pubitemid 27495778)
40. Guilpain P, Servettaz A, Batteux F, Guillevin L, Mouthon L. Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies. Autoimmun Rev. 2008;7(6):421-5.
41. Guilpain P, Servettaz A, Goulvestre C, Barrieu S, Borderie D, Chereau C, et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum. 2007;56(7):2455-63. (Pubitemid 47173595)
42. Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev. 2003;2(3):158-64. (Pubitemid 37443853)
43. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol. 2004;93(4):398-401. (Pubitemid 39382982)
44. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis. 2005;45(4):758-61. (Pubitemid 40460764)
45. Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol. 2000;18(3):404-6. (Pubitemid 30409116)
46. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004;63(12):1649-54. (Pubitemid 39573697)
47. Levy Y, George J, Fabbrizzi F, Rotman P, Paz Y, Shoenfeld Y. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J. 1999;92(4):412-4. (Pubitemid 29197496)
48. Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58(1):308-17.
49. Muso E, Ito-Ihara T, Ono T, Imai E, Yamagata K, Akamatsu A, et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis. 2004;57(5):S17-8.
50. Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol. 2009;158 Suppl 1:43-50.
51. Shoenfeld Y. 5th International symposium on IVIG: IVIG in the third millenium, 25-27 September 2003, Interlaken, Switzerland. Autoimmun Rev. 2004;3(3):234-41. (Pubitemid 38521100)
52. Takigawa N, Kawata N, Shibayama T, Tada A, Kimura G, Munemasa M, et al. Successful treatment of a patient with severe Churg-Strauss syndrome by a combination of pulse corticosteroids, pulse cyclophosphamide, and high-dose intravenous immunoglobulin. J Asthma. 2005;42(8):639-41. (Pubitemid 41609529)
53. Taniguchi M, Tsurikisawa N, Higashi N, Saito H, Mita H, Mori A, et al. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int. 2007;56(2):97-103. (Pubitemid 46984237)
54. Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92(1):80-7. (Pubitemid 38113636)
55. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010;30 Suppl 1:S9-14.
56. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008;105(50):19571-8.
57. Kaneko Y, Nimmerjahn F, Ravetch JV. A + Science. 2006;313(5787):670-3.
58. Makhoul B, Braun E, Herskovitz M, Ramadan R, Hadad S, Norberto K. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J. 2009;11:151-3.
59. Ben-Nathan D, Gershoni-Yahalom O, Samina I, Khinich Y, Nur I, Taub O, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis. 2009;9:18.